
Orchestra BioMed Holdings Investor Relations Material
Latest events

Q1 2025
11 May, 2025

Q4 2024
30 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Orchestra BioMed Holdings Inc
Access all reports
Orchestra BioMed Holdings, Inc. is a biomedical innovation company focused on accelerating the development and commercialization of high-impact medical technologies. The company operates through a partnership-enabled business model, collaborating with leading medical device companies to bring its innovations to market. Its key product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT), which is designed to treat hypertension in patients with pacemakers, and Virtue Sirolimus AngioInfusion Balloon (SAB), intended for the treatment of atherosclerotic artery disease. Orchestra BioMed has strategic partnerships with companies like Medtronic and Terumo Corporation to advance the development and global commercialization of these products. The company is headquartered in New Hope, Pennsylvania, and its shares are listed on the Nasdaq.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
OBIO
Country
🇺🇸 United States